Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
NCT06952517
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Papular-pustular Rosacea
- Papulopustular Rosacea (PPR)
- Papulopustular Rosacea
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Narrows Institute for Biomedical Research
- Last updated on ClinicalTrials.gov
- May 6, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- New York Harbor VA Brooklyn Campus · Brooklyn, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.